Can Test Reports Be Reused for Medical Device Registration in Australia?

Key Summary

Yes, test report reuse is feasible for medical device registration in Australia, but only under strict conditions. The laboratory must be ISO 17025 accredited or equivalent, and testing must align with standards recognised by the Australian Therapeutic Goods Administration (TGA), such as the IEC 60601 series. For low-risk devices (Class I, Class I Is measuring/sterile), full reuse of reports from the country of origin (e.g., China NMPA) is often possible if the reports cover mandatory Australian standard differences. For higher-risk classes (Class IIa, IIb, III), the TGA may require supplementary local testing or documented conversions for biocompatibility, electrical safety, or clinical evaluation. The core decision-making logic involves confirming the TGA classification pathway, verifying whether existing reports are based on the latest standards, and checking whether Australian-specific voltage or environmental condition tests are included. Manufacturers must prepare a technical file gap analysis, a standards comparison table, and laboratory qualification evidence. Common risks include outdated standard versions, missing Australian-specific tests (e.g., AS/NZS standards), non-recognised laboratories, and insufficient post-market performance tracking data. We recommend engaging a professional regulatory consultancy for a gap assessment early in the project to avoid costly corrections or rejection.

Applicable Scenarios and Core Questions

The question of whether test reports can be reused for Australian registration is a common issue for manufacturers planning global registrations. The TGA, as a member of the GHWP, recognises certain internationally accepted test data, but acceptance is not unconditional. Test report reuse mainly applies to type testing, electrical safety, electromagnetic compatibility (EMC), and biocompatibility—physical or chemical performance verification—but does not cover clinical evaluation or quality management system audits.

Reuse typically applies when the same product has already obtained market approval in China (NMPA), the European Union (CE), or the United States (FDA 510(k)), and the testing standards are substantially aligned with TGA requirements. However, the TGA's acceptance depends on product risk classification, standard version differences, laboratory qualification, and whether Australian-specific test items are included.

For active medical devices, the IEC 60601 series is adopted in Australia as the AS/NZS 60601 series. Technical content is highly consistent, but there may be annexes or national differences. If the original test report covers all clauses of AS/NZS 60601, including national differences, direct reuse is possible; otherwise, supplementary differential testing is required. For in vitro diagnostics (IVDs), reuse conditions are stricter because the TGA has specific requirements for IVD classification and performance evaluation, such as standards for positive/negative reference materials.

Additionally, test reports are not valid indefinitely. The TGA generally requires reports to be issued within the last five years. Any changes to product design, manufacturing processes, or key raw materials may require reassessment.

Another key point is software and wireless communication functions. If the product includes Bluetooth, Wi-Fi, or other wireless modules, the TGA requires radio frequency testing under AS/NZS 4268, which may differ slightly from CE or FCC requirements. When reusing such reports, confirm that test frequencies and limits are compatible.

Overall, test report reuse can significantly reduce registration costs and timelines, but only if the manufacturer conducts a systematic gap analysis and provides a complete evidence chain proving the report's validity and applicability.

Registration Decision-Making Logic

Before deciding whether to reuse existing test reports, follow these steps:

• Step 1: Confirm whether the product falls under TGA regulatory scope. Under the Therapeutic Goods Act, all devices for human diagnosis, prevention, monitoring, or treatment require registration, except for certain custom-made or exempt products.
• Step 2: Determine the product risk classification. The TGA uses a rule-based system with classes from low to high risk: Class I, Class I Is/Im, Class IIa, Class IIb, Class III, and Active Implantable Medical Devices. Classification determines the registration pathway (pre-market notification or full evaluation) and the level of TGA scrutiny. Low-risk devices enjoy more flexible report reuse; high-risk devices typically require full testing.
• Step 3: Assess the source and standards of existing reports. If reports come from NMPA, a CE notified body, or an FDA-recognized laboratory, and use standards adopted by the TGA (e.g., ISO 13485, IEC 60601 series, ISO 10993 series), reuse is more likely. However, you must compare against the TGA's 'relevant standards list' and national differences.
• Step 4: Confirm technical file completeness. Besides test reports, the TGA requires a quality management system certificate (ISO 13485 or MDSAP), design documentation, risk management report (ISO 14971), clinical evaluation or performance assessment data, labels and instructions for use (English version), and Australian local agent or authorised representative information. A test report is only part of the technical file and cannot replace other elements.
• Step 5: Consider post-market maintenance obligations. Reusing reports does not exempt the manufacturer from post-market surveillance, adverse event reporting, and periodic updates. The TGA may require ongoing verification data or accept site audits, especially for implantable devices.

Documentation and Evidence

To successfully reuse test reports, prepare the following core documents:

• Full copies of original test reports: Include test methods, equipment information, results, and data summaries, issued by a qualified third-party laboratory (e.g., CNAS, UKAS, ANAB accredited).
• Standards gap analysis table: Clearly list differences between the international standard used (e.g., IEC 60601-1:2005+A1:2012) and the Australian standard adopted by the TGA (AS/NZS 60601.1:2015), explaining whether the original report covers all differences or provide a supplementary testing plan.
• Laboratory qualification evidence: CNAS certificate, ILAC-MRA mark, or equivalent to prove ISO 17025 compliance and that the accreditation scope covers the tested items.
• Product and design change declaration: If the product has changed post-market, provide a change list and an assessment of the impact on test reports. If changes affect safety or performance, the original report cannot be reused.
• Quality management system documents: ISO 13485 or MDSAP certificate, and manufacturing site registration (if applicable). For other system certifications, provide mutual recognition agreements or equivalence statements.
• Local agent authorisation letter: Australian regulations require overseas manufacturers to appoint a local agent (Sponsor) who bears legal responsibility. The agent must confirm and sign technical documents, including a declaraton of test report applicability.
• Biocompatibility reports: If reusing, confirm the version of ISO 10993 standards and add TGA-specific requirements for sensitisation, cytotoxicity, etc.
• Label and instruction draft: English versions must comply with TGA labelling regulations, including warnings, symbol meanings, and UMLS codes (if applicable). Performance data in test reports must align with label claims.

Common Mistakes

• Assuming all NMPA reports are automatically accepted by the TGA: The TGA has strict laboratory qualification requirements. Not all Chinese testing institutions are TGA-recognised or covered by MRA agreements. Verify that the laboratory is CNAS-accredited and covered by ILAC-MRA.
• Ignoring standard version differences: Even if standard numbers are the same, versions may differ. For example, IEC 60601-1 third edition and fourth edition have significant differences. The TGA usually adopts the latest version, so older reports may be invalid.
• Failing to consider Australian-specific voltage, frequency, and environmental condition tests: Australia's grid voltage is 230V/50Hz. Some products may require additional low-voltage adaptability or tropical climate testing.
• Confusing clinical evaluation with test reports: Clinical trial data or published literature cannot replace type test reports; their purposes differ. Reusing test reports does not exempt clinical evaluation, especially for high-risk products.
• Overlooking software and wireless testing: Products with software or wireless modules require separate software validation reports and radio frequency test reports (AS/NZS 4268), which may not have equivalent requirements under CE or FDA.
• Failing to update agent and certificate control: The TGA requires registration certificates and test reports to be held by the Australian agent, and any changes must be notified. If the agent changes or certificates expire, reused reports may not pass annual reviews.

Preparation Checklist for Manufacturers

• Confirm the correct TGA classification (citing the HSCF rules) and the registration pathway (ordinary or full evaluation).
• Collect all existing test reports (electrical safety, EMC, biocompatibility, performance, etc.) and note issuing agency and standard versions.
• Download the latest TGA 'relevant standards list' and national differences documents, then check report coverage item by item.
• Contact the original testing laboratory to confirm ISO 17025 accreditation and provide ILAC-MRA certificate.
• For missing or non-compliant test items, develop a supplementary testing or third-party testing plan. Consider using TGA-recognised laboratories in Australia or Singapore to reduce TGA queries.
• Compile a complete technical file including risk management report (ISO 14971), QMS certificate, English labels and instructions, clinical evaluation report (if required), and performance verification summary.
• Appoint a local agent (Sponsor) and sign an agency agreement defining responsibilities and document custody requirements.
• Conduct an internal gap analysis and retain records as supporting evidence for the registration application. If necessary, hire a TGA-savvy consultant for pre-review.
• Prepare a 'Test Report Reuse Declaration' signed by an authorised manufacturer representative, stating the report validity, standards comparison results, and coverage.
• Establish a post-market surveillance (PMS) plan, including adverse event reporting procedures and Periodic Safety Update Report (PSUR) writing standards, to ensure post-registration compliance.

Our Perspective (AIMEILI)

In our experience with hundreds of multi-country registration projects, the most common misjudgments in Australian report reuse concern laboratory qualifications and standard versions. Many manufacturers assume that reports accepted by NMPA are automatically accepted by the TGA, but the TGA requires laboratories to be ILAC-MRA recognised and the standards to be the latest versions. For example, an active device tested to IEC 60601-1 third edition in 2021 may face correction if the TGA adopted the fourth edition by 2022. We recommend that the first step in any project is to obtain the current TGA-recognised laboratory list and standards list, then perform a quick comparison with existing reports. This step takes less than half a day but can avoid months of rework.

Which documents can be reused? Generally, pure physical/chemical performance tests (dimensions, strength, composition analysis) and general safety standards (ISO 14971 risk management reports, ISO 10993-1 biocompatibility preliminary assessments) have higher reuse rates. However, clinical evaluation, stability data, software validation, and special environmental tests (tropical shock, high altitude) require localisation or re-validation. Quality management system certificates such as ISO 13485 or MDSAP can be directly reused, but only if the certificate covers Australia and the system gap conversion is performed.

On the importance of local agents: Many manufacturers view agents as mere signatories, but in reality, the agent is responsible for holding technical documents, monitoring changes, and communicating with the TGA. An unqualified agent may lose control of certificates or fail to notify the TGA of product changes, leading to registration invalidation. We recommend choosing an experienced regulatory service company as an agent rather than a purely commercial partner.

For multi-country registration strategies, we recommend modularising core documents (test reports, risk management, QMS) and then performing gap adjustments for each country. For instance, a single EMC report can satisfy both CE (EN 55011) and TGA (AS/NZS 2064) by simply annotating the correspondence. This greatly reduces recompilation and correction risk. In summary, test report reuse is a feasible shortcut, but it must be built on professional gap analysis and a complete evidence chain.

Frequently Asked Questions (FAQ)

Q: Our product has a Class III medical device registration certificate in China, and the test report was just completed. Can we directly use it for TGA registration in Australia?

A: Not directly. You first need to confirm whether the Chinese testing laboratory holds CNAS accreditation with ILAC-MRA qualification, and whether the standards used in the report match the versions adopted by the TGA. Moreover, for Class III (high risk) products, the TGA usually requires more comprehensive review and may require supplementary testing per Australian-specific standards. For example, some biocompatibility items may need to be repeated according to the latest version of ISO 10993-1. We recommend a gap analysis first; at minimum, a standards difference declaration and individual supplementary tests are typically needed.

Q: How much time can reusing test reports save?

A: If full reuse is possible without supplementary testing, you can save 2-3 months of testing time. However, the registration process itself still takes 6-12 months, depending on product category and review queues. Supplementary testing adds another 1-2 months. Overall, reuse reduces preparation time, but the total registration duration is more influenced by TGA efficiency and documentation completeness.

Q: Does the TGA accept FDA or CE test reports?

A: The TGA accepts CE and FDA reports through different mechanisms. For CE reports, if a notified body recognised the laboratory and the testing was based on EN standards, the TGA accepts them in principle but requires a standards comparison table and difference statements against AS/NZS. For FDA reports, because the US uses UL standards or FDA-specific test methods, the TGA typically does not accept them directly. Re-testing to AS/NZS standards is required unless the laboratory holds A2LA or other MRA qualifications and can issue reports compliant with Australian standards. We recommend consulting the TGA or a professional agent early in the project.

Additionally, if applying for registration in multiple countries simultaneously (e.g., China, EU, Australia), consider conducting testing to international standards (IEC, ISO) in one go, and request laboratories to issue a multi-standard coverage list. International laboratories such as SGS, TÜV, or UL often provide 'one-stop' multi-standard testing, which effectively reduces redundant costs.

Recommended Reading

• How to Use ISO 13485 Certificates for Medical Device Registration in Australia
• How to Choose a Local Agent for Medical Device Registration in Australia
• How to Divide Responsibilities of Authorised Representatives for Medical Device Registration in Australia
• Why Does Medical Device Registration in Australia Take Longer?
• Common Reasons for Request for Additional Information in Australian Medical Device Registration
• How to Conduct Post-Market Surveillance for Medical Devices in Australia